Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Blood - 1 Aug 2002

Roche-Lestienne Catherine, Soenen-Cornu Valerie, Grardel-Duflos Nathalie, Laï Jean-Luc, Philippe Nathalie, Facon Thierry, Fenaux Pierre, Preudhomme Claude

Abstract excerpt

Targeting the tyrosine kinase activity of BCR-ABL represents a very promising therapeutic strategy in chronic myeloid leukemia (CML). Despite strong efficacy of the tyrosine kinase inhibitor STI571, resistance has been observed in a significant proportion of patients in advanced CML stage or in Ph-positive acute lymphoid leukemia (ALL). We investigated in this study the mechanism of resistance to STI571 through...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Clone Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Identifiers

PMID: 12130516
DOI: 10.1182/blood.v100.3.1014

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.PMID 12130516Read ↗

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.Semantic proximity Read ↗

Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571.Semantic proximity Read ↗

Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.Semantic proximity Read ↗

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemiaSemantic proximity Read ↗

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.Semantic proximity Read ↗

Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutationSemantic proximity Read ↗

Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia.Semantic proximity Read ↗

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemiaSemantic proximity Read ↗

Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplificationSemantic proximity Read ↗

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Semantic proximity Read ↗

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationSemantic proximity Read ↗

[Novel inhibitors of Bcr-Abl].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.